| XLS |
|
|
|
€ million |
Q1 – 2014 |
Q1 – 2013 |
Sales |
2,613.9 |
2,660.4 |
Royalty, license and commission income |
51.0 |
100.1 |
Total revenues |
2,664.8 |
2,760.5 |
|
|
|
Cost of sales |
–736.5 |
–724.0 |
Gross profit |
1,928.3 |
2,036.5 |
|
|
|
Marketing and selling expenses |
–549.5 |
–568.3 |
Royalty, license and commission expenses |
–136.4 |
–136.3 |
Administration expenses |
–132.3 |
–132.7 |
Other operating expenses and income |
–66.8 |
–184.0 |
Research and development costs |
–378.9 |
–406.2 |
Amortization of intangible assets |
–196.1 |
–209.6 |
Operating result (EBIT) |
468.3 |
399.4 |
|
|
|
Financial result |
–34.7 |
–58.7 |
Profit before income tax |
433.6 |
340.7 |
|
|
|
Income tax |
–106.1 |
–71.7 |
Profit after tax |
327.4 |
269.0 |
|
|
|
of which attributable to Merck KGaA shareholders (net income) |
325.2 |
266.0 |
of which attributable to non-controlling interests |
2.2 |
3.0 |
|
|
|
Earnings per share (in €) |
|
|
basic |
1.50 |
1.22 |
diluted |
1.50 |
1.22 |
back
